Navigation Links
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
Date:8/22/2008

timing of these activities. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of expeditious review attributed to Fast Track Designation, the Company's ability to rapidly advance development programs, the strength of the combined oncology product pipeline, the timing of clinical trials and development efforts and the results of clinical and pre-clinical studies are all forward-looking statements. The potential risks and uncertainties include, among others, the possibility that Fast Track Designation will not expedite the development timing or the FDA review of OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier clinical trial results, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities, as well as other risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. A more complete discussion of risks and uncertainties that may affect forward-looking statements is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007, and its Quarterly Report on Form 10-Q for the first quarter of 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of the Company. The Company undertakes no ob
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline To Post Quarterly US Grants Report
2. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
5. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
10. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
11. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... State of Qatar to Introduce State-of-the-Art Treatments including ... the leading cancer centers in the Middle East ... Medical Systems (NYSE: VAR ) equipped ... Al Amal Hospital in Doha, Qatar, is replacing ...
... EU, LATAM and AfricaSAINT JOHN, New Brunswick, March 11 ... of ThyroChek, the rapid test for elevated TSH, the ... European Union. Until now, it has only been offered ... adults to the 200,000 physician office labs. With the ...
... Conference Call on Wednesday, March 11, 2009 at 4:30 ... - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... and fiscal year 2008 financial results, reviewed the Company,s ... was a tremendously active year from an execution standpoint ...
Cached Biology Technology:Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 3OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 5OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 6OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 7OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 8OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 9OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 11OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 12
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... gas seeping from the melting Arctic ice cap told Jeff ... permafrost thaws, there is a release of methane, a powerful ... figuring out how much, said Chanton, the John W. Winchester ... team whose findings were published in the respected journal ...
... at Baylor College of Medicine and Texas Children,s ... intestine that produce a neurotransmitter that may play ... diseases such as Crohn,s disease. "We identified, ... dentium, that is capable of secreting large amounts ...
... Department has recognized the University of Calgary, Sport Injury ... and preventing sports injuries. The Sport Injury Prevention ... named one of the IOC,s four international sport injury ... held on June 18, from 6 7:30pm at ...
Cached Biology News:Study: Seeking Arctic methane has serious implications for Florida coastline 2Intestinal bacteria produce neurotransmitter, could play role in inflammation 2IOC recognizes University of Calgary Sports Injury Research Prevention Centre 2
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... FROM MOISTURE. AVOID FREEZE/THAW CYCLES. This kit ... in vitro by DNA affinity-mediated capture ... detection. In this assay, mono- and oligonucleosomes ... Anti-Histone 3 (H3) biotin-labeled antibody then binds ...
Biology Products: